Reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-06. Numbers and descriptions here follow the published literature rather than marketing material.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Bioanalyzer: The bioanalyzer is an instrument that uses electrophoresis to separate and analyze DNA, RNA, and protein samples. It can provide detailed information about the size, integrity, and purity of a DNA sample.
Jessie Gordon, formerly McTavish, (born c.1940) is a Scottish retired nurse who was convicted in 1974 of murdering a patient with insulin, and of administering a variety of substances with intent to cause harm. The conviction was overturned on appeal in 1976. She was dubbed the "Angel of Death" by the press.
=== EC 1.5.3 With oxygen as acceptor === EC 1.5.3.1: sarcosine oxidase EC 1.5.3.2: N-methyl-L-amino-acid oxidase EC 1.5.3.3: deleted EC 1.5.3.4: N6-methyl-lysine oxidase EC 1.5.3.5: (S)-6-hydroxynicotine oxidase EC 1.5.3.6: (R)-6-hydroxynicotine oxidase EC 1.5.3.7: L-pipecolate oxidase EC 1.5.3.8: Now included with EC 1.3.3.8, tetrahydroberberine oxidase EC 1.5.3.9: Now EC 1.21.3.3, reticuline oxidase EC 1.5.3.10: dimethylglycine oxidase EC 1.5.3.11: Now included with EC 1.5.3.13 (N1-acetylpolyamine oxidase), EC 1.5.3.14 (polyamine oxidase (propane-1,3-diamine-forming)), EC 1.5.3.15 (N8-acetylspermidine oxidase (propane-1,3-diamine-forming)), EC 1.5.3.16 (spermine oxidase) and EC 1.5.3.17 (non-specific polyamine oxidase) EC 1.5.3.12: dihydrobenzophenanthridine oxidase EC 1.5.3.13: N1-acetylpolyamine oxidase EC 1.5.3.14: polyamine oxidase (propane-1,3-diamine-forming) EC 1.5.3.15: N8-acetylspermidine oxidase (propane-1,3-diamine-forming) EC 1.5.3.16: spermine oxidase EC 1.5.3.17: non-specific polyamine oxidase EC 1.5.3.18: L-saccharopine oxidase EC 1.5.3.19: 4-methylaminobutanoate oxidase (formaldehyde-forming) EC 1.5.3.20: N-alkylglycine oxidase EC 1.5.3.21: 4-methylaminobutanoate oxidase (methylamine-forming) EC 1.5.3.22: coenzyme F420H2 oxidase EC 1.5.3.23: glyphosate oxidoreductase
Sources: en.wikipedia.org
=== Sources === Philippe Jaussaud; Édouard-Raoul Brygoo (2004). Du Jardin au Muséum. Archives (in French). Paris: Muséum national d'histoire naturelle. p. 630. ISBN 978-2-85653-565-3. Annuaire et sites du Muséum national d'histoire naturelle, 40 p., MNHN, Paris, rééditions décennales. Ghislaine Prévos, Service documentation du Département des Galeries du Muséum national d'histoire naturelle, annuaire biographique du personnel.
Weather observation quality control systems verify probability, history, and trends. One of the main and simplest forms of quality control is the check of probability. This check throws out impossible observations, such as the dew point being higher than the temperature or data outside acceptable ranges, such as temperatures over 200 degrees Fahrenheit. Another basic quality control check is to have the data compared to preset geographic extremes, perhaps combined with diurnal variations. However this only flags the data as uncertain because the station could be reporting correctly but there is no way to know. A better way is to correlate with previous observations as well as the other simple checks. This method uses one hour persistence to check the quality of the current observation. This method makes continuity of observations better since the system is able to make better judgments on whether the current observations are bad or not.
Chromatin remodelers in the INO80 subfamily are made of multiple subunit complexes with split ATPase domains. The INO80 subfamily's protein domains are an N-terminus, two RuvB-like proteins (Rvb1 and Rvb2), and a C-terminus. The ATPase domain of the N-terminus functions in the identification of DNA damage and aids in the stability of telomeres. A long insertion in the ATPase domain is what recruits the Rvb1 and Rvb2 helicases. These helicases contribute to genome maintenance and are unique to the INO80 subfamily of chromatin remodeling complexes. This subfamily also contains an Arp4-actin complex that aids in stability of genes. The Arp5 subunit is required for ATPase function, binding to the DNA, and relocation of nucleosomes.
Chemokine (C-C motif) ligand 7 (CCL7) is a small cytokine that was previously called monocyte-chemotactic protein 3 (MCP3). CCL7 is a small protein that belongs to the CC chemokine family and is most closely related to CCL2 (previously called MCP1). In the human genome, CCL7 is encoded by the CCL7 gene which is one of the several chemokine genes clustered on chromosome 17q11.2-q12. This region contains the gene for the MCP subset of CC chemokines. The CCL7 gene has been given the locus symbol SCYA7. The gene consists of three exons and two introns. The first exon contains a 5′-untranslated region (5′-UTR), the information for the signal sequence (23 amino acids), and the mature protein's first two amino acids. The second exon encodes amino acids 3–42 of the mature proteins. The third exon is composed of the C-terminal region of the protein, a 3′-UTR containing one or more destabilizing AU-rich sequences and a polyadenylation signal.
Sources: en.wikipedia.org
There are numerous signals given off that initiate hunger. There are environmental signals, signals from the gastrointestinal system, and metabolic signals that trigger hunger. The environmental signals come from the body's senses. The feeling of hunger could be triggered by the smell and thought of food, the sight of a plate, or hearing someone talk about food. The signals from the stomach are initiated by the release of the peptide hormone ghrelin. Ghrelin is a hormone that increases appetite by signaling to the brain that a person is hungry. Environmental signals and ghrelin are not the only signals that initiate hunger, there are other metabolic signals as well. As time passes between meals, the body starts to take nutrients from long-term reservoirs. When the glucose levels of cells drop (glucoprivation), the body starts to produce the feeling of hunger. The body also stimulates eating by detecting a drop in cellular lipid levels (lipoprivation). Both the brain and the liver monitor the levels of metabolic fuels. The brain checks for glucoprivation on its side of the blood–brain barrier (since glucose is its fuel), while the liver monitors the rest of the body for both lipoprivation and glucoprivation.
Taha Othman Ishaq (or Osman), a lawyer and member of the FFC negotiating committee, declined his nomination by the FFC to the Sovereignty Council on the grounds that the FFC alliance had earlier agreed that members of the negotiating committee should not become members of the Sovereignty Council. Raja Nicola was the civilian member of the Sovereignty Council mutually chosen by the FFC and TMC. The choice of Nicola, as a member of the Sudanese Copt community, is seen as a symbol of respect for diversity, in particular to Sudanese Christians. On 4 February 2021, al-Burhan issued a decree to add three new members to the Council. The new members are Sudanese Revolutionary Front leader El Hadi Idris Yahya, Sudan People's Liberation Movement-North leader Malik Agar, and Sudan Liberation Movement for Justice-Karbino leader El Tahrir Abubakr Hajar.
== Animal requirements == All vertebrate and chordate species require vitamin A, either as dietary carotenoids or preformed retinol from consuming other animals. Deficiencies have been reported in laboratory-raised and pet dogs, cats, birds, reptiles and amphibians, also commercially raised chickens and turkeys. Herbivore species such as horses, cattle and sheep can get sufficient β-carotene from green pasture to be healthy, but the content in pasture grass dry due to drought and long-stored hay can be too low, leading to vitamin A deficiency. Omnivore and carnivore species, especially those toward the top of the food chain, can accrue large amounts of retinyl esters in their livers, or else excrete retinyl esters in urine as a means of dealing with surplus. Before the era of synthetic retinol, cod liver oil, high in vitamins A and D, was a commonly consumed dietary supplement. Invertebrates cannot synthesize carotenoids or retinol, and thus must accrue these essential nutrients from consumption of algae, plants or animals.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.